4D pharma PLC (AIM:DDDD, NASDAQ:LBPS) announced the appointment of John Doyle as chief financial officer.
The pharmaceutical company, which specialises in the development of live biotherapeutic products, said Doyle will become a member of the management team, bringing with him over 15 years of experience.
He joins having previously held senior positions in pharmaceutical companies, such as vice president of finance and investor relations at Verastem and director of business unit financial planning & analysis in the Early Phase Division at PAREXEL (NASDAQ:PRXL), both publicly traded companies.
Earlier in his career, he served in senior financial planning and analysis roles at Hologic (NASDAQ:HOLX) Inc, a Nasdaq-listed provider of medical diagnostic, surgical and imaging products.
Duncan Peyton, chief executive officer of 4D pharma, said: "John's extensive financial experience in diverse healthcare organizations and transformational events will be invaluable as 4D pharma continues to make progress in the clinic on multiple fronts with our Live Biotherapeutic programs."
Doyle added: "The 4D pharma team has built an impressive pipeline across key areas of high unmet need and I am excited for the opportunity to execute on the company's growth strategy and financial goals."